UAB Digital Repository of Documents 10 records found  Search took 0.01 seconds. 
1.
7 p, 1.1 MB Multidisciplinary management of head and neck cancer : First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1) / Mañós, M. (Hospital Universitari de Bellvitge) ; Giralt, J. (Hospital Universitari Vall d'Hebron) ; Rueda, A. (Hospital Costa del Sol (Marbella)) ; Cabrera, J. (Hospital Infanta Cristina) ; Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ; Marruecos, J. (ICO Girona) ; López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ; Rodrigo, J.P. (Hospital Universitario Central de Asturias) ; Castelo, B. (Hospital Universitario La Paz (Madrid)) ; Martínez-Galán, J. (Hospital Universitario Virgen de las Nieves (Granada)) ; Arias, F. (Complejo Hospitalario de Navarra) ; Chaves, M. (Hospital de Valme) ; Herranz, J.J. (Complejo Hospitalario Universitario de A Coruña) ; Arrazubi, V. (Hospital de Basurto (Bilbao, Biscaia)) ; Basté, Neus (Hospital Universitari Vall d'Hebron) ; Castro, A. (Hospital Universitario La Paz (Madrid)) ; Mesía, R. (ICO L'Hospitalet de Llobregat) ; Universitat Autònoma de Barcelona
Head and neck cancer is one of the most frequent malignances worldwide. Despite the site-specific multimodality therapy, up to half of the patients will develop recurrence. Treatment selection based on a multidisciplinary tumor board represents the cornerstone of head and neck cancer, as it is essential for achieving the best results, not only in terms of outcome, but also in terms of organ-function preservation and quality of life. [...]
2017 - 10.1016/j.oraloncology.2017.04.004
Oral Oncology, Vol. 70 (july 2017) , p. 58-64  
2.
5 p, 347.5 KB SEOM clinical guideline in nasopharynx cancer (2017) / Pastor, M. (Hospital La Fe de València) ; López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ; del Barco, E. (Complejo Asistencial Universitario de Salamanca) ; Perez Segura, P. (Hospital Clínico San Carlos (Madrid)) ; Astorga, B.G. (Hospital Universitario San Cecilio (Granada)) ; Castelo, B. (Hospital Universitario La Paz (Madrid)) ; Bonfill Abella, Teresa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Martinez Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ; Grau, Juan Jose (Hospital Clínic i Provincial de Barcelona) ; Mesía, Ricard (Institut Català d'Oncologia) ; Universitat Autònoma de Barcelona
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiation therapy is an essential component of curative-intent of non-disseminated disease and the association of chemotherapy improves the rates of survival. [...]
2018 - 10.1007/s12094-017-1777-0
Clinical & Translational Oncology, Vol. 20 Núm. 1 (january 2018) , p. 84-88  
3.
12 p, 2.3 MB HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients' survival / Taberna, Miren (Universitat de Barcelona) ; Mena, Marisa (Centro de Investigación Biomédica en Red de Cáncer) ; Tous, Sara (Centro de Investigación Biomédica en Red de Cáncer) ; Pavón, Miquel Angel (Centro de Investigación Biomédica en Red de Cáncer (CIBERESP)) ; Oliva, Marc (Hospital Universitari de Bellvitge) ; León i Vintró, Xavier (Institut d'Investigació Biomèdica Sant Pau) ; Garcia Lorenzo, J (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Guix, Marta (Hospital del Mar (Barcelona, Catalunya)) ; Hijano, Rafael (Hospital del Mar (Barcelona, Catalunya)) ; Bonfill Abella, Teresa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Aguilà, Antón (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Alemany, Laia (Centro de Investigación Biomédica en Red de Cáncer (CIBERESP)) ; Mesía, Ricard (Institut Català d'Oncologia) ; Universitat Autònoma de Barcelona
Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associated with human papillomavirus (HPV) infection, a novel clinical stage classification for HPV-related OPC has been accepted for the 8 edition AJCC TNM (ICON-S model). [...]
2018 - 10.1371/journal.pone.0194107
PloS one, Vol. 13 Núm. 4 (april 2018) , p. e0194107  
4.
12 p, 2.4 MB The use of HPV16-E5, EGFR, and PEGFR as prognostic biomarkers for oropharyngeal cancer patients / Taberna, Miren (Hospital Universitari de Bellvitge) ; Torres, Montserrat (Hospital Universitari de Bellvitge) ; Alejo, María (Hospital General de l'Hospitalet) ; Mena, Marisa (Centro de Investigación Biomédica en Red de Cáncer) ; Tous, Sara (Centro de Investigación Biomédica en Red de Cáncer) ; Marquez, Sandra (Hospital Universitari de Bellvitge) ; Pavón, Miquel A. (Hospital Universitari de Bellvitge) ; León, Xavier (Institut d'Investigació Biomèdica Sant Pau) ; Garcia Lorenzo, J (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Guix, Marta (Hospital del Mar (Barcelona, Catalunya)) ; Hijano, Rafael (Hospital del Mar (Barcelona, Catalunya)) ; Bonfill Abella, Teresa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Aguilà, Antón (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Lozano, Alicia (Hospital Universitari de Bellvitge) ; Mesía, Ricard (Hospital Universitari de Bellvitge) ; Alemany, Laia (Hospital Universitari de Bellvitge) ; Bravo, Ignacio G. (Laboratory MIVEGEC (CNRS IRD Uni Montp)) ; Universitat Autònoma de Barcelona
Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on deescalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. [...]
2018 - 10.3389/fonc.2018.00589
Frontiers in Oncology, Vol. 8 Núm. DEC (2018) , p. 589  
5.
11 p, 1018.7 KB Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe / Mena, Marisa (Hospital Universitari de Bellvitge) ; Frias-Gomez, Jon (Hospital Universitari de Bellvitge) ; Taberna, Miren (Hospital Universitari de Bellvitge) ; Quirós, Beatriz (Hospital Universitari de Bellvitge) ; Marquez, Sandra (Hospital Universitari de Bellvitge) ; Clavero, Omar (de Hospital Universitari de Bellvitge) ; Baena, Antoni. (Hospital Universitari de Bellvitge) ; Lloveras, Belén (Hospital del Mar (Barcelona, Catalunya)) ; Alejo, María (Hospital General de l'Hospitalet) ; León i Vintró, Xavier (Institut d'Investigació Biomèdica Sant Pau) ; García, Jacinto Montero (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ; Mesía, Ricard (Institute Catala Oncologia) ; Bermejo, Josep Oriol (Hospital Universitari de Bellvitge) ; Bonfill Abella, Teresa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Aguilà, Antón (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Guix, Marta (Hospital del Mar (Barcelona, Catalunya)) ; Hijano, Rafael (Hospital del Mar (Barcelona, Catalunya)) ; Pavón, Miguel Ángel (Hospital Universitari de Bellvitge) ; Torres, Montserrat A. (Hospital Universitari de Bellvitge) ; Tous, Sara (Hospital Universitari de Bellvitge) ; Clèries, Ramón (Hospital Universitari de Bellvitge) ; Alemany, Laia (Hospital Universitari de Bellvitge) ; Universitat Autònoma de Barcelona
The incidence of human papillomavirus (HPV)-related oropharyngeal cancer is increasing in some regions. Nevertheless, the epidemiology of this disease has not been extensively investigated in southern Europe. [...]
2020 - 10.1038/s41598-020-70118-7
Scientific reports, Vol. 10 Núm. 1 (january 2020) , p. 13219  
6.
20 p, 1.9 MB Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types / Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gutiérrez-Chamorro, Lucía (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Gómez, Maica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García Vidal, Edurne (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Romeo, Margarita (Universitat Autònoma de Barcelona. Departament de Medicina) ; Morán, Teresa (Universitat Autònoma de Barcelona. Departament de Medicina) ; Layos, Laura (Universitat Autònoma de Barcelona. Departament de Medicina) ; Pérez-Roca, Laia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Riveira-Muñoz, Eva (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Fernández, Pedro Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesía, Ricard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ballana, Ester (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ample evidence exists connecting dNTP pool dysregulation to cancer and genomic instability. SAMHD1, the unique dNTP triphosphohydrolase described in humans, has been proposed to play a key role in hematological cancers, although its value in advanced solid tumors has not yet been explored. [...]
2022 - 10.20944/preprints202201.0141.v1
Cancers, Vol. 14 Núm. 3 (january 2022)  
7.
19 p, 1.6 MB Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma / García-Foncillas, Jesús (Universidad Autónoma de Madrid. Departamento de Medicina) ; Tejera-Vaquerizo, Antonio (Hospital San Juan de Dios (Còrdova, Espanya)) ; Sanmartín, Onofre (Fundació Institut Valencià d'Oncologia) ; Rojo, Federico (Hospital Universitario Fundación Jiménez Díaz) ; Mestre, Javier (Hospital Universitario Miguel Servet (Saragossa)) ; Martín, Salvador (Clínica Universidad de Navarra) ; Azinovic, Ignacio (Hospital Universitario Fundación Jiménez Díaz) ; Mesía, Ricard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, which predominantly occurs on the head and neck. Early detection and treatment of primary tumours is crucial to limit progression and local invasion of deep tissues. [...]
2022 - 10.3390/cancers14030629
Cancers, Vol. 14 Núm. 3 (january 2022)  
8.
503.0 KB p16, HPV, and Cetuximab : What Is the Evidence? / Bonner, James A. (University of Alabama at Birmingham Comprehensive Cancer Center) ; Mesia, Ricard (Institut d'Investigació Biomèdica de Bellvitge) ; Giralt López de Sagredo, Jordi (Hospital Universitari Vall d'Hebron) ; Psyrri, Amanda (National Kapodistrian University of Athens) ; Keilholz, Ulrich (Charité Comprehensive Cancer Center) ; Rosenthal, David I. (The University of Texas, MD Anderson Cancer Center) ; Beier, Frank (Merck KGaA) ; Schulten, Jeltje (Merck KGaA) ; Vermorken, Jan B. (University Hospital Antwerp (Bèlgica)) ; Universitat Autònoma de Barcelona
This study reviews available methodologies for evaluating human papillomavirus (HPV) status, as well as current evidence involving the prognostic and potential predictive value of p16 and HPV status in patients with locoregionally advanced or recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab combination regimens, with an emphasis placed on recent subgroup analyses of the phase III IMCL-9815 and EXTREME trials. [...]
2017 - 10.1634/theoncologist.2016-0433
The Oncologist, Vol. 22 (may 2017) , p. 811-822  
9.
11 p, 877.0 KB Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma : Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy / Zandberg, Dan P. (University of Pittsburgh Medical Center. Hillman Cancer Center) ; Algazi, Alain P. (University of California San Francisco Helen Diller Family Comprehensive Cancer Center) ; Jimeno, Antonio (Division of Medical Oncology. University of Colorado School of Medicine) ; Good, James S. (Institute of Head and Neck Studies and Education. Queen Elizabeth Hospital) ; Fayette, Jérôme (Clinical Oncology. Cancer Center Centre Léon Bérard. University of Lyon) ; Bouganim, Nathaniel (Department of Oncology. McGill University Health Centre) ; Ready, Neal E. (Duke University Medical Center) ; Clement, Paul M. (Department of Oncology. Leuven Cancer Institute) ; Even, Caroline (Institut Gustave Roussy (Villejuif, França)) ; Jang, Raymond W. (Princess Margaret Cancer Centre. University of Toronto) ; Wong, Stuart (Division of Hematology Oncology. Medical College of Wisconsin) ; Keilholz, Ulrich (Charité Comprehensive Cancer Center) ; Gilbert, Jill (Henry-Joyce Cancer Clinic) ; Fenton, Moon (The West Cancer Center. University of Tennessee Health Science Center) ; Braña, Irene (Vall d'Hebron Institut d'Oncologia) ; Henry, Stephanie (Department of Oncology-Hematology. Radiotherapy. and Nuclear Medicine. CHU UCL Namur) ; Remenar, Eva (National Institute of Oncology (Országos Onkológiai Intézet)) ; Papai, Zsuzsanna (State Health. Center Higatian Defanse Forses) ; Siu, Lillian L. (Princess Margaret Cancer Centre. University of Toronto) ; Jarkowski, Anthony (AstraZeneca) ; Armstrong, Jon M. (AstraZeneca) ; Asubonteng, Kobby (AstraZeneca) ; Fan, Jean (AstraZeneca) ; Melillo, Giovanni (AstraZeneca) ; Mesía, Ricard (Institut d'Investigació Biomèdica de Bellvitge) ; Universitat Autònoma de Barcelona
Background: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) progressing on platinum-based chemotherapy have poor prognoses and limited therapeutic options. Programmed cell death-1 (PD-1) and its ligand 1 (PD-L1) are frequently upregulated in HNSCC. [...]
2019 - 10.1016/j.ejca.2018.11.015
European journal of cancer, Vol. 107 (january 2019) , p. 142-152  
10.
18 p, 288.5 KB Translational research opportunities regarding homologous recombination in ovarian cancer / Romeo, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pardo, Juan Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Quiroga, Vanesa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Román, Sergio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesía, Ricard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ovarian carcinomas (HGSOC). Deficient HR (DHR) constitutes a therapeutic opportunity for these patients, thanks to poly (ADP-ribose) polymerases (PARP) inhibitors (PARPi; olaparib, niraparib, and rucaparib are already commercialized). [...]
2018 - 10.3390/ijms19103249
International journal of molecular sciences, Vol. 19 Núm. 10 (19 2018) , p. 3249  

See also: similar author names
4 Mesia, R.
9 Mesia, Ricard
9 Mesía, Ricard
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.